Estradiol benzoate/hydroxyprogesterone caproate explained

Estradiol benzoate/hydroxyprogesterone caproate (EB/OHPC), sold under the brand name Primosiston among others, is a combined estrogen and progestogen medication which is used to treat gynecological disorders and habitual abortion.[1] [2] [3] [4] [5] It contains estradiol benzoate (EB), an estrogen, and hydroxyprogesterone caproate (OHPC), a progestin. The medication is given by injection into muscle.

Medical uses

EB/OHPC is used in the treatment of gynecological disorders such as menstrual disorders (e.g., amenorrhea, dysfunctional uterine bleeding) and premenstrual syndrome, habitual abortion (threatened miscarriage), and for other indications.

Available forms

EB/OHPC is available in the form of ampoules of oil solutions containing 10 mg estradiol benzoate (EB) and 125 to 250 mg hydroxyprogesterone caproate (OHPC).

History

EB/OHPC was first introduced for medical use in 1955.[6]

Society and culture

Brand names

EB/OHPC has been marketed under brand names including Dos Dias N, Lutes, Ostrolut, Primosiston (or Primosiston Inj. / Injection), Primosiston Fuerte, and Syngynon.

Availability

EB/OHPC has been mostly discontinued and hence is mostly no longer available.[7] [8] [9] It remains marketed under the brand names Primosiston in Ecuador and Peru, Dos Dias N in Argentina, and Lutes in Japan. It was previously marketed under the brand names Ostrolut in Austria; Primosiston (or Primosiston Inj. / Injection) (Schering) in Argentina, Germany, Mexico, Switzerland, and Venezuela; Primosiston Fuerte in Spain; and Syngynon in Germany, but these formulations have all been discontinued and hence are no longer available in these countries.

See also

Notes and References

  1. Book: Leidenberger FA . Klinische Endokrinologie für Frauenärzte. 17 April 2013. Springer-Verlag. 978-3-662-08110-5. 533–.
  2. Book: Knörr K, Beller FK, Lauritzen C . Lehrbuch der Gynäkologie. 17 April 2013. Springer-Verlag. 978-3-662-00942-0. 255–.
  3. Book: Kahr H . Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. 8 March 2013. Springer-Verlag. 978-3-7091-5694-0. 22–.
  4. Book: Kern W, Auterhoff H, Neuwald F, Schmid W . Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. 9 March 2013. Springer-Verlag. 978-3-642-49759-9. 1163–.
  5. Book: Die Gestagene. 27 November 2013. Springer-Verlag. 978-3-642-99941-3. 1045–.
  6. Kaiser R . Gestagen-Östrogen-Kombinationen in der Gynäkologie. Zur Geschichte, Dosierung und Anwendung eines Hormonprinzips . Progestogen-Estrogen Combinations in Gynecology. History, Dosage, and Use of a Hormone Principle . Geburtshilfe und Frauenheilkunde . 53 . 7 . 2008 . 503–513 . 0016-5751 . 10.1055/s-2007-1022924 . 8370495 . Zur kombinierten Anwendung von Gestagen en und Östrogenen stand en zunächst ölgelöstes Östradiolbenzoat und Progesteron zur Verfügung. Das erste derartige Mischpräparat kam in Deutschland 1950 auf den Mark t. Dem Wunsch nach verlän gerter Wirkungsdauer entsprach en dann Kristallmischsuspension en verschiedener Korngröße aus Östradiolmonobenzoat + Progesteron, deren Anwendung sich auf klinische Untersuchungen besch ränkte (83). Ölgelöste Depotpräparate mit Östradiolbenzoat oder -valerat + 17-hydroxyprogesteroncaproat wurden ab 1955 in die Therapie eingeführt (45.46)..
  7. Web site: Hydroxyprogesterone. Drugs.com. May 27, 2019.
  8. Book: Sweetman SC . Sex hormones and their modulators . Martindale: The Complete Drug Reference . 36th . 2009 . 2082 . Pharmaceutical Press . London. 978-0-85369-840-1.
  9. Web site: Micromedex Products: Please Login. www.micromedexsolutions.com. May 27, 2019.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Estradiol benzoate/hydroxyprogesterone caproate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.